Want to see MDT full AI Analyst Report?
MDT Stock Chart & Stats
$92.02
$1.71(2.06%)
At close: 4:00 PM EDT
$92.02
$1.71(2.06%)
Day’s Range― - ―
52-Week Range$73.31 - $106.33
Previous CloseN/A
Volume1.79M
Average Volume (3M)25.23M
Market Cap
$118.67B
Enterprise Value$129.69B
Total Cash (Recent Filing)$8.82B
Total Debt (Recent Filing)$28.15B
Price to Earnings (P/E)23.2
Beta0.30
Next Earnings
Nov 24, 2026EPS Estimate
1.33Next Dividend Ex-DateN/A
Dividend Yield3.08%
Share Statistics
EPS (TTM)4.09
Shares Outstanding1,279,169,900
10 Day Avg. Volume48,811,130
30 Day Avg. Volume25,233,251
Financial Highlights & Ratios
PEG Ratio6.72
Price to Book (P/B)2.16
Price to Sales (P/S)2.94
P/FCF Ratio19.68
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue3.45
Enterprise Value/Gross Profit5.18
Enterprise Value/Ebitda12.74
Forecast
1Y Price Target
$103.19Price Target Upside12.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)5.98
Revenue Forecast (FY)$39.05B
Bulls Say, Bears Say
Bulls Say
Cash GenerationStrong operating and free cash flow provide Medtronic with durable internal funding for research, acquisitions, debt service, and shareholder returns. The 13% increase in free cash flow also supports resilience and gives management flexibility to invest through changing procedure and reimbursement environments.
Raised Growth GuidanceHigher full-year growth and profit guidance indicates management sees broad-based demand and operating leverage extending beyond a single product or quarter. Expected margin expansion alongside revenue growth suggests the portfolio can convert improved commercial momentum into stronger earnings over coming periods.
Cardiac Ablation MomentumExceptional cardiac ablation growth and measurable share gains strengthen Medtronic’s position in an important therapy category. The expanding Affera and Sphere-9 platform can support recurring procedure-driven revenue, deepen physician adoption, and create a durable foundation for future electrophysiology expansion.
Bears Say
Elevated DebtAlthough equity supports a moderate debt-to-equity profile, the sizable absolute debt balance can reduce financial flexibility if growth slows or capital costs rise. Higher leverage may constrain acquisition capacity, increase refinancing exposure, and compete with innovation or shareholder-return priorities.
Cash Conversion PressureOperating cash flow below reported earnings suggests working-capital or timing factors are limiting near-term cash realization. If this persists, it could weaken the reliability of accounting profits as a funding source and reduce flexibility for investment, debt reduction, and capital allocation.
Neuromodulation WeaknessSlow neuromodulation growth indicates pressure in an established portfolio, with both market softness and replacement dynamics affecting demand. Continued weakness could restrain Neuroscience performance, dilute growth from stronger businesses, and require additional innovation or commercial investment to restore momentum.
Medtronic News
MDT FAQ
What was Medtronic’s price range in the past 12 months?
Medtronic lowest stock price was $73.31 and its highest was $106.33 in the past 12 months.
What is Medtronic’s market cap?
Medtronic’s market cap is $118.67B.
When is Medtronic’s upcoming earnings report date?
Medtronic’s upcoming earnings report date is Nov 24, 2026 which is in 35 days.
How were Medtronic’s earnings last quarter?
Medtronic released its earnings results on Sep 01, 2026. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.388 by $0.062.
Is Medtronic overvalued?
According to Wall Street analysts Medtronic’s price is currently Undervalued.
Does Medtronic pay dividends?
Medtronic pays a Quarterly dividend of $0.72 which represents an annual dividend yield of 3.08%. See more information on Medtronic dividends here
What is Medtronic’s EPS estimate?
Medtronic’s EPS estimate is 1.33.
How many shares outstanding does Medtronic have?
Medtronic has 1,279,169,900 shares outstanding.
What happened to Medtronic’s price movement after its last earnings report?
Medtronic reported an EPS of $1.45 in its last earnings report, beating expectations of $1.388. Following the earnings report the stock price went up 1.534%.
Which hedge fund is a major shareholder of Medtronic?
Currently, no hedge funds are holding shares in MDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medtronic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$103.19 (12.14% Upside)
$103.19 (12.14% Upside)
Blogger Sentiment
Bullish
MDT Sentiment 77%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.06%
12-Months-Change
Fundamentals
Return on Equity
10.60%
Trailing 12-Months
Asset Growth
2.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medtronic
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
MDT Company Deck
MDT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Medtronic reported broad-based revenue and earnings outperformance, significant growth in Cardiac Ablation Solutions, continued momentum in CRM, CST, Surgical, Pelvic Health and Diabetes, improved operating metrics, stronger cash conversion and raised fiscal 2027 guidance. The principal challenges were business-mix pressure on gross margin, neuromodulation softness, low-single-digit Structural Heart growth, expected moderation in some growth rates, and foreign exchange and tariff headwinds.View all MDT earnings summariesMDT Net sales Breakdown
36.56% Cardiovascular
29.06% Neuroscience
26.01% Medical Surgical
7.69% Diabetes
0.68% Other operating segment
MDT Stock 12 Month Forecast
Average Price Target
$103.19
▲(12.14% Upside)
Technical Analysis
Ownership Overview
0.07% Insiders
25.54% Mutual Funds
1.24% Other Institutional Investors
49.12% Public Companies and Individual Investors